{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:21:42Z","timestamp":1761862902864,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.jsat.2010.02.002","type":"journal-article","created":{"date-parts":[[2010,4,2]],"date-time":"2010-04-02T04:33:58Z","timestamp":1270182838000},"page":"338-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin"],"prefix":"10.1016","volume":"38","author":[{"given":"Michael","family":"Waizmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grit","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2010.02.002_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drugpo.2007.04.004","article-title":"Global estimates of prevalence of HCV infection among injecting drug users","volume":"18","author":"Aceijas","year":"2007","journal-title":"International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2010.02.002_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/521166","article-title":"Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial","volume":"45","author":"Altice","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2010.02.002_bib3","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/588297","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994\u20132004","volume":"46","author":"Amon","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2010.02.002_bib4","doi-asserted-by":"crossref","first-page":"A775","DOI":"10.1016\/S0016-5085(08)63618-5","article-title":"Drug users with chronic hepatitis C who are adherent to antiviral treatment will finally benefit from therapy","volume":"134","author":"Anagnostou","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jsat.2010.02.002_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2008.08.009","article-title":"Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone\/buprenorphine maintenance therapy","volume":"41","author":"Belfiori","year":"2009","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.jsat.2010.02.002_bib6","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/j.1572-0241.2008.02065.x","article-title":"Efficacy and safety of peginterferon alfa-2a\/ribavirin in methadone maintenance patients: Randomized comparison of direct observed therapy and self-administration","volume":"103","author":"Bonkovsky","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.jsat.2010.02.002_bib7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.gcb.2008.07.004","article-title":"A French prospective observational study of the treatment of chronic hepatitis C in drug abusers","volume":"32","author":"Chossegros","year":"2008","journal-title":"Gastroent\u00e9rologie Clinique et Biologique"},{"key":"10.1016\/j.jsat.2010.02.002_bib8","first-page":"393A","article-title":"Feasibility of combination therapy for chronic hepatitis C in IVDU in the framework of a heroin detoxification protocol","volume":"46","author":"Ciaccio","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2010.02.002_bib9","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1086\/421404","article-title":"Directly observed therapy for the management of HIV-infected patients in a methadone program","volume":"38","author":"Conway","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2010.02.002_bib10","first-page":"68","article-title":"Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice","volume":"68","author":"de Bie","year":"2005","journal-title":"Acta Gastroenterologica Belg"},{"key":"10.1016\/j.jsat.2010.02.002_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.44.2.104","article-title":"A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jsat.2010.02.002_bib12","first-page":"341","article-title":"Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV\/human immunodeficiency virus coinfection. Seminars in Liver Disease, 25, 18\u201332","volume":"18","author":"Dore","year":"2005","journal-title":"Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2010.02.002_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2010.02.002_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.drugpo.2007.01.009","article-title":"Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection","volume":"18","author":"Grebely","year":"2007","journal-title":"International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2010.02.002_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2010.02.002_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.drugpo.2007.01.016","article-title":"HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection","volume":"18","author":"Hagan","year":"2007","journal-title":"International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2010.02.002_bib17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C","volume":"7","author":"Hauser","year":"2002","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jsat.2010.02.002_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000104884","article-title":"Hepatitis C treatment of opioid dependants receiving maintenance treatment: Results of a Norwegian pilot study","volume":"13","author":"Krook","year":"2007","journal-title":"European Addiction Research"},{"key":"10.1016\/j.jsat.2010.02.002_bib19","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1086\/427450","article-title":"Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities","volume":"40","author":"Litwin","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2010.02.002_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2004.04.058","article-title":"Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C","volume":"365","author":"Loftis","year":"2004","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.jsat.2010.02.002_bib21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1086\/503905","article-title":"Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups","volume":"42","author":"Lucas","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2010.02.002_bib22","doi-asserted-by":"crossref","first-page":"S409","DOI":"10.1086\/421405","article-title":"Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study","volume":"38","author":"Lucas","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2010.02.002_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2036.2007.03568.x","article-title":"De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C","volume":"27","author":"Mart\u00edn-Santos","year":"2008","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.jsat.2010.02.002_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10461-007-9336-2","article-title":"Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy","volume":"12","author":"Maru","year":"2008","journal-title":"AIDS and Behaviour"},{"key":"10.1016\/j.jsat.2010.02.002_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2010.02.002_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jsat.2010.02.002_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2007.01.007","article-title":"A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C","volume":"103","author":"Morasco","year":"2007","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.jsat.2010.02.002_bib28","first-page":"1","volume":"Vol. 19","author":"NIH Consensus Statement on Management of Hepatitis C: 2002","year":"2002"},{"key":"10.1016\/j.jsat.2010.02.002_bib29","first-page":"41","article-title":"Management of chronic hepatitis in drug addicts: A systematic review","volume":"159","author":"Pellicelli","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jsat.2010.02.002_bib30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2007.03316.x","article-title":"Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C","volume":"25","author":"Raison","year":"2007","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.jsat.2010.02.002_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","article-title":"Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes","volume":"18","author":"Robaeys","year":"2006","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.jsat.2010.02.002_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2010.02.002_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.psy.45.2.176","article-title":"Depression during treatment with interferon alpha","volume":"45","author":"Schaefer","year":"2004","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jsat.2010.02.002_bib34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2005.01.020","article-title":"Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C","volume":"42","author":"Schaefer","year":"2005","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jsat.2010.02.002_bib35","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/01.qai.0000248338.74943.85","article-title":"Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users","volume":"43","author":"Smith-Rohrberg","year":"2006","journal-title":"Acquired Immune Deficiency Syndrome"},{"key":"10.1016\/j.jsat.2010.02.002_bib36","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2010.02.002_bib37","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/376911","article-title":"Anemia in the treatment of hepatitis C virus infection","volume":"37","author":"Sulkowski","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2010.02.002_bib38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/MEG.0b013e3281bcb8d8","article-title":"Adherence to hepatitis C treatment in recovering heroin users maintained on methadone","volume":"19","author":"Sylvestre","year":"2007","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.jsat.2010.02.002_bib39","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1111\/j.1572-0241.2003.07702.x","article-title":"Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse","volume":"98","author":"van Thiel","year":"2003","journal-title":"American Journal of Gastroenterology"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547210000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547210000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:33:54Z","timestamp":1760038434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547210000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0740547210000292"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2010.02.002","relation":{},"ISSN":["0740-5472"],"issn-type":[{"type":"print","value":"0740-5472"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2010.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}